These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 31094591)

  • 21. IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy.
    Tagliaferri A; Molinari AC; Peyvandi F; Coppola A; Demartis F; Biasoli C; Borchiellini A; Cultrera D; De Cristofaro R; Daniele F; Giordano P; Marchesini E; Margaglione M; Marino R; Pollio B; Radossi P; Santoro C; Santoro RC; Siragusa S; Sottilotta G; Tosetto A; Piscitelli L; Villa MR; Zanon E; Finardi A; Schiavetti I; Vaccari D; Castaman G
    Haemophilia; 2023 Jan; 29(1):135-144. PubMed ID: 36423202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B.
    Klamroth R; Bonner A; Gomez K; Monahan PE; Szafranski K; Zhang X; Walsh S; Wang D; Yan S
    Haemophilia; 2024 Jan; 30(1):75-86. PubMed ID: 37902714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice.
    Mancuso ME; Oldenburg J; Boggio L; Kenet G; Chan A; Altisent C; Seifert W; Santagostino E
    Haemophilia; 2020 Jul; 26(4):637-642. PubMed ID: 32542961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B.
    Lemons R; Wang M; Curtin J; Lepatan LM; Male C; Peyvandi F; von Depka Prondzinski M; Wang R; McKeand W; Seifert W; Oldenburg J
    TH Open; 2024 Jan; 8(1):e155-e163. PubMed ID: 38532939
    [No Abstract]   [Full Text] [Related]  

  • 25. Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats.
    Herzog E; Harris S; Henson C; McEwen A; Schenk S; Nolte MW; Pragst I; Dickneite G; Schulte S; Zollner S
    Thromb Res; 2014 May; 133(5):900-7. PubMed ID: 24680550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain.
    Rodríguez López M; Megías Vericat JE; Albo López C; Bonanad S
    BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33051199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pattern of use and clinical outcomes with rIX-FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real-world study.
    Giordano P; Pollio B; Sottilotta G; Biasoli C; Daniele F; De Cristofaro R; Peyvandi F; Villa MR; Castaman G;
    Eur J Haematol; 2024 May; 112(5):765-775. PubMed ID: 38223989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX-Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective-Prospective Study.
    Coppola A; Rivolta GF; Quintavalle G; Matichecchia A; Riccardi F; Rossi R; Benegiamo A; Ranalli P; Coluccio V; Tagliaferri A
    J Clin Med; 2024 Mar; 13(5):. PubMed ID: 38592343
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.
    Santagostino E; Negrier C; Klamroth R; Tiede A; Pabinger-Fasching I; Voigt C; Jacobs I; Morfini M
    Blood; 2012 Sep; 120(12):2405-11. PubMed ID: 22859609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.
    Preijers T; van Spengler MWF; Meijer K; Fijnvandraat K; Fischer K; Leebeek FWG; Cnossen MH; Mathôt RAA
    Eur J Clin Pharmacol; 2022 Feb; 78(2):237-249. PubMed ID: 34651201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program.
    Laws HJ; Fukutake K; Lopez-Fernandez MF; Li Y; Seifert W; Tagliaferri A
    Eur J Haematol; 2023 Aug; 111(2):293-299. PubMed ID: 37232041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits of rIX-FP prophylaxis in patients with Haemophilia B: real-world evidence from a Spanish reference centre.
    Benítez-Hidalgo O; Bosch Schips M; Juárez Giménez JC; Gironella M
    Hematology; 2023 Dec; 28(1):2242656. PubMed ID: 37680021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GlycoPEGylated recombinant factor IX for hemophilia B in context.
    Santagostino E; Mancuso ME
    Drug Des Devel Ther; 2018; 12():2933-2943. PubMed ID: 30254423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP.
    Curtin J; Santagostino E; Karim FA; Li Y; Seifert W; Négrier C
    Thromb Res; 2020 Apr; 188():85-89. PubMed ID: 32109773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.
    Chia J; Louber J; Glauser I; Taylor S; Bass GT; Dower SK; Gleeson PA; Verhagen AM
    J Biol Chem; 2018 Apr; 293(17):6363-6373. PubMed ID: 29523681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients.
    Pabinger I; Lissitchkov T; Nagao A; Lepatan LM; Li Y; Seifert W; Mancuso ME
    Res Pract Thromb Haemost; 2023 May; 7(4):100195. PubMed ID: 37538501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue distribution of rIX-FP after intravenous application to rodents.
    Herrmann S; Doerr B; May F; Kuehnemuth B; Cherpokova D; Herzog E; Dickneite G; Nolte MW
    J Thromb Haemost; 2020 Dec; 18(12):3194-3202. PubMed ID: 32810892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging drugs for hemophilia B.
    Mannucci PM; Franchini M
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):407-14. PubMed ID: 25098797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data.
    Escobar M; Mancuso ME; Hermans C; Leissinger C; Seifert W; Li Y; McKeand W; Oldenburg J
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.